Marathon launches needle-free device ZiNGO to manage venous access pain

9 September 2014 (Last Updated September 9th, 2014 18:30)

US-based Marathon Pharmaceuticals has launched ZiNGO (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system, to deliver a topical local anaesthetic to manage venous access pain.

Zingo

US-based Marathon Pharmaceuticals has launched ZiNGO (lidocaine hydrochloride monohydrate, 0.5mg) powder intradermal injection system, to deliver a topical local anaesthetic to manage venous access pain.

With the push of a button, the needle-free, easy to use, handheld device ZiNGO delivers a 0.5mg dose of powdered lidocaine particles into the skin through a helium-powered delivery system, numbing the site in one to three minutes.

The device can be incorporated into a medical procedure requiring venous access, allowing uninterrupted care.

The company said that ZiNGO is sterile, for single-use and does not need to be refrigerated.

Intravenous (IV) cannulations are one of the worst sources of pain for children in paediatric hospitals, and the anxiety associated with needles often requires children to be controlled for blood draws and IV starts.

The new ZiNGO offers relief for these patients by delivering a powdered form of lidocaine that numbs the site prior to needle insertion.

"ZiNGO is the first easy-to-administer, fast-acting topical local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures in children."

Connecticut Children's Medical Center professor of paediatrics and division head of Pain and Palliative Medicine William Zempsky said: "ZiNGO is the first easy-to-administer, fast-acting topical local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures in children.

"Because commonly available local anaesthetic products can take up to 30 to 60 minutes to work, making incorporation into the busy healthcare environment difficult, healthcare providers have had to sacrifice patient comfort when performing the numerous venous access procedures that occur each day. ZiNGO will be a source of relief to children and parents."

Initially, the company will focus on providing ZiNGO to children's hospitals, medical centres and community hospitals.

Marathon commercial operations vice-president Tom Larson said: "We recognise the high demands on clinicians caring for patients.

"ZiNGO has an onset of action in as little as one to three minutes, enabling nurses to reduce pain at the needle insertion site easily and efficiently in the busy hospital setting."


Image: ZiNGO is a hand-held device that delivers a 0.5 mg dose of powdered lidocaine particles into the skin through a helium-powered delivery system. Photo: courtesy of Business Wire.